The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling.

Ikezoe, Takayuki

The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling. [electronic resource] - Molecular cancer therapeutics Oct 2006 - 2522-30 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1535-7163

10.1158/1535-7163.MCT-06-0071 doi


Adaptor Proteins, Signal Transducing--antagonists & inhibitors
Antineoplastic Agents--pharmacology
Apoptosis
Cell Cycle Proteins
Cell Line, Tumor
Cell Proliferation--drug effects
Drug Synergism
Everolimus
Hematologic Neoplasms--enzymology
Humans
Indoles--pharmacology
Leukemia--metabolism
Mutation
Phosphoproteins--antagonists & inhibitors
Protein Kinases--physiology
Pyrroles--pharmacology
Receptor Protein-Tyrosine Kinases--genetics
Ribosomal Protein S6 Kinases, 70-kDa--antagonists & inhibitors
Signal Transduction
Sirolimus--analogs & derivatives
Sunitinib
TOR Serine-Threonine Kinases